XML 54 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Equity
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Equity
29.
Equity
 
29.1.
Share capital
 

  
2024
    
2023
    
2022
    
2024
    
2023
    
2022
  
 
  
Number ‘000
    
Number ‘000
    
Number ‘000
    
A$’000
    
A$’000
    
A$’000
  
Balance at January 1,
  

323,727
      
316,343
      
285,073
      
446,268
      
370,972
      
170,840
  
Shares issued through the exercise of share options and warrants1
    
525
      
3,879
      
8,543
      
8,080
      
42,572
      
32,948
  
Contributions of equity2
    
-
      
-
      
22,727
      
-
      
-
      
175,000
  
Shares issued for Dedicaid3
    
-
      
207
      
-
      
-
      
1,829
      
-
  
Shares issued for Lightpoint4
    
-
      
3,298
      
-
      
-
      
30,895
      
-
  
Shares issued for IsoTherapeutics5
    
718
      
-
      
-
      
8,912
      
-
      
-
  
Shares issued for ARTMS6
    
5,675
      
-
      
-
      
71,610
      
-
      
-
  
Shares issued for QSAM7
    
4,080
      
-
      
-
      
61,906
      
-
      
-
  
Transaction costs arising on new share issues
    
-
      
-
       -      
-
      
-
      
(7,816
)
Balance at December 31,
    
334,725
      
323,727
      
316,343
      
596,776
      
446,268
      
370,972
  
 

 1.
Options exercised during the year through the employee Equity Incentive Plan resulted in 525,000 (2023: 3,879,000, 2022: 8,543,000) shares being issued of total value of $8,080,000 (2023: $42,572,000, 2022: $32,948,000).
 

 2.
On January 27,2022, the Group completed a $175,000,000 institutional placement of 22,727,000 new, fully paid ordinary shares at a price of $7.70 per share. As part of this placement, the Group also incurred $7,816,000 of associated transaction costs.
 

 3.
On April 27, 2023, the Group completed the acquisition of Dedicaid GmbH. The consideration for the acquisition comprised 207,000 in Telix shares at a 10-day volume weighted average price of shares on the execution date of $8.73 per share.
 

 4.
On November 1, 2023, the Group completed the acquisition of Lightpoint through the issue of 3,298,000 fully paid ordinary Telix shares at $9.3659 per share.


5.
On April 9, 2024, the Group completed the acquisition of IsoTherapeutics. The consideration included the issue of 717,587 fully paid ordinary Telix shares at $12.42 per share.


6.
On April 11, 2024, the Group completed the acquisition of ARTMS. The consideration included the issue of 5,674,365 fully paid ordinary Telix shares at $12.62 per share.


7.
On May 3, 2024, the Group completed the acquisition of QSAM. The purchase price included the issue of 3,671,120 fully paid ordinary Telix shares at $14.80 per share and a further 409,026 fully paid ordinary Telix shares at $18.05 per share.

The weighted average ordinary shares for the period January 1, 2024 to December 31, 2024 is 331,226,491 (2023: 319,180,783). The Company does not have a limited amount of authorized capital under Australian law.
 
Rights applying to securities:
 
1.
Ordinary shares: Ordinary shares entitle the holder to participate in dividends, and to share in the proceeds of winding up the Company in proportion to the number of and amounts paid on the shares held.
 
2.
Options and rights: Holders of Options and rights have no voting rights. Information relating to the Company’s Employee Incentive Plan (EIP), including details of Options issued, exercised and lapsed during the financial year, is set out in note 30.
 
29.2.
Share capital reserve
 

  
2024
    
2023
    
2022
    
2024
    
2023
    
2022
  
 
  
Number ’000
    
Number ’000
    
Number ‘000
    

A$’000
    

A$’000
    

A$’000
  
Balance at January 1
   -

-

-


(62,829
)
    
(26,909
)
    
-
  
Treasury shares acquired
    
525
      
3,877
      
4,054
      
(7,081
)
    
(35,920
)
    
(26,909
)
Issue of convertible bonds
    -       -       -       97,900
    -


-  
Transaction costs arising on convertible bonds issue
    -
       -
       -
       (2,245
 )
     -


-  
Shares allocated to employees
    
(525
)
    
(3,877
)
    
(4,054
)
    
-
      
-
      
-
  
Balance at December 31
    
-
      
-
      
-
      
25,745
      
(62,829
)
    
(26,909
)
 
29.2.1.
Treasury shares
 
Ordinary shares in the Company were purchased by the Telix Pharmaceuticals Employee Share Trust for the purpose of issuing shares under the Equity Incentive Plan. These shares are allocated to employees and are not held within the Employee Share Trust (see note 30 for further information).
 
29.2.2.
Conversion right of convertible bonds
 
The amount shown for the issue of convertible bonds is the initial value of the conversion rights relating to the convertible bonds.

29.3.
Other reserves



 

Foreign currency
translation reserve
    

Share-based
payments reserve
    

Financial assets at
FVOCI reserve
    


Total
  
 
  

A$‘000
    

A$’000
    

A$’000
    

A$’000
  
Balance as at January 1, 2024
    
(5,414
)
    
35,446
      
(895
)
    
29,137
  
Other comprehensive income
    
47,684
      
-
      
(4,986
)
    
42,698
  
Total comprehensive income    
47,684
      
-
      
(4,986
)
    
42,698
  
Share-based payments to employees    
-
      
19,660
      
-
      
19,660
  
Share-based payments associated with acquisitions
    -
       67,943       -       67,943  
Transfer on exercise of options
    -
       (784 )     -       (784 )
      -
       86,819       -       86,819  
Balance as at December 31, 2024
    
42,270
      
122,265
      
(5,881
)
    
158,654
  


 
Foreign currency
translation reserve
    
Share-based
payments reserve
    
Financial assets at
FVOCI reserve
    
Total
  
 
  

A$‘000
    

A$’000
    

A$’000
    

A$’000
  
Balance as at January 1, 2023
    
(562
)
    
9,321
      
-
      
8,759
  
Other comprehensive income
    
(4,852
)
    
-
      
(895
)
    
(5,747
)
Total comprehensive loss    
(4,852
)
    
-
      
(895
)
    
(5,747
)
Share-based payments to employees    
-
      
8,786
      
-
      
8,786
  
Share-based payments associated with acquisitions
    -       21,278       -       21,278  
Transfer on exercise of options
    -       (3,939 )     -       (3,939 )
      -       26,125       -       26,125  
Balance as at December 31, 2023
    
(5,414
)
    
35,446
      
(895
)
    
29,137
  


 
Foreign currency
translation reserve
    
Share-based
payments reserve
    
Financial assets at
FVOCI reserve
    
Total
  
 
  

A$‘000
    

A$’000
    

A$’000
    

A$’000
  
Balance as at January 1, 2022
    
(1,153
)
    
5,942
      
-
      
4,789
  
Other comprehensive income
    
591
      
-
      
-
      
591
  
Total comprehensive income/(loss)    
591
      
-
      
-
      
591
  
Share-based payments to employees    
-
      
8,114
      
-
      
8,114
  
Transfer on exercise of options
    -       (4,735 )     -       (4,735 )
      -       3,379       -       3,379  
Balance as at December 31, 2022
    
(562
)
    
9,321
      
-
      
8,759
  

29.4.
Share-based payments reserve
 

  
2024
    
2023
    
2022
  
 
  
Number ’000
    
Number ’000
    
Number ‘000
  
Balance at January 1
   14,601     11,736     17,148  
EIP options issued
    
9,877
      
6,689
      
4,436
  
Performance Rights issued1
    
4,284
      
2,524
      
-
  
Options exercised
    
(619
)
    
(4,524
)
    
(8,843
)
Options lapsed
    
(2,621
)
    
(1,824
)
    
(1,005
)
Balance at December 31
    
25,522
      
14,601
      
11,736
  
 
1.
Relates to the acquisition of QSAM in the current period and Lightpoint in the prior year.
 
29.5.
 Financial assets at FVOCI reserve
 
The group has elected to recognize changes in the fair value of certain investments in equity securities in Other comprehensive income (OCI), as explained in note 16. These changes are accumulated within the FVOCI reserve within equity.
 
The table below shows how the FVOCI reserve relates to equity securities:
 

  
2024
    
2023
    
2022
  
 
  
A$’000
    
A$’000
    
A$’000
  
Balance at January 1
  

(895
)
    
-
      
-
  
Revaluation - gross
    
(4,986
)
    
(895
)
    
-
  
Deferred tax
    
-
      
-
      
-
  
Balance at December 31
    
(5,881
)
    
(895
)
    
-